In the latest quarter, 28 analysts provided ratings for Axsome Therapeutics AXSM, showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 16 | 12 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 3 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 2 | 0 | 0 | 0 |
| 3M Ago | 11 | 9 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $177.11, a high estimate of $216.00, and a low estimate of $133.00. Marking an increase of 9.75%, the current average surpasses the previous average price target of $161.38.
Investigating Analyst Ratings: An Elaborate Study
A clear picture of Axsome Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Leonid Timashev | RBC Capital | Raises | Outperform | $193.00 | $190.00 |
| Andrew Tsai | Jefferies | Announces | Buy | $200.00 | - |
| Raghuram Selvaraju | HC Wainwright & Co. | Maintains | Buy | $200.00 | $200.00 |
| Ami Fadia | Needham | Maintains | Buy | $153.00 | $153.00 |
| Graig Suvannavejh | Mizuho | Raises | Outperform | $216.00 | $212.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Maintains | Buy | $200.00 | $200.00 |
| Ami Fadia | Needham | Maintains | Buy | $153.00 | $153.00 |
| Joel Beatty | Baird | Raises | Outperform | $160.00 | $132.00 |
| Vikram Purohit | Morgan Stanley | Raises | Overweight | $190.00 | $125.00 |
| Graig Suvannavejh | Mizuho | Raises | Outperform | $212.00 | $195.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Maintains | Buy | $200.00 | $200.00 |
| Ami Fadia | Needham | Maintains | Buy | $153.00 | $153.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Raises | Buy | $200.00 | $190.00 |
| Joon Lee | Truist Securities | Raises | Buy | $200.00 | $190.00 |
| Leonid Timashev | RBC Capital | Raises | Outperform | $192.00 | $143.00 |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $153.00 | $153.00 |
| Ami Fadia | Needham | Raises | Buy | $153.00 | $133.00 |
| Cerena Chen | Wells Fargo | Raises | Overweight | $160.00 | $140.00 |
| David Hoang | Deutsche Bank | Announces | Buy | $176.00 | - |
| Jason Gerberry | B of A Securities | Raises | Buy | $167.00 | $143.00 |
| Graig Suvannavejh | Mizuho | Raises | Outperform | $195.00 | $137.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Maintains | Buy | $190.00 | $190.00 |
| Marc Goodman | Leerink Partners | Raises | Outperform | $150.00 | $110.00 |
| Ami Fadia | Needham | Maintains | Buy | $133.00 | $133.00 |
| Graig Suvannavejh | Mizuho | Raises | Outperform | $137.00 | $122.00 |
| Joon Lee | Truist Securities | Raises | Buy | $190.00 | $180.00 |
| Brian Abrahams | RBC Capital | Raises | Outperform | $143.00 | $139.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Raises | Buy | $190.00 | $180.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Axsome Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Axsome Therapeutics compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Axsome Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into Axsome Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Axsome Therapeutics analyst ratings.
About Axsome Therapeutics
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Understanding the Numbers: Axsome Therapeutics's Finances
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Axsome Therapeutics's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 66.04%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Axsome Therapeutics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -63.08%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Axsome Therapeutics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -99.94%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Axsome Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -13.26%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Axsome Therapeutics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 3.38, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
How Are Analyst Ratings Determined?
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
